Key indicators: single-crystal X-ray study; T = 163 K; mean (C-C) = 0.002 Å; R factor = 0.040; wR factor = 0.094; data-to-parameter ratio = 15.2.
In the title molecule, C 17 H 14 O 4 , the C atom of the carboxyl group deviates by 1.221 (3) Å from the plane [maximum deviation = 0.0122(2) Å ] of the tricycic ring system. In the crystal structure, intermolecular O-HÁ Á ÁO hydrogen bonds link the molecules into centrosymmetric dimers, andinteractions [centroid-centroid distances = 3.491 (3), 3.591 (3), 3.639 (3) and 3.735 (3) Å ] link these dimers into layers parallel to the ac plane. Weak intermolecular C-HÁ Á ÁO interactions further consolidate the crystal packing.
Related literature
For general background to and recent reviews of vasculardisrupting agents and the development of Vadimezan (DMXAA, ASA404), a promising small-molecule tumorvascular disrupting agent in phase III clinical trials, see: McKeage & Baguley (2010) ; Head & Jameson (2010) ; Ching (2008) ; Patterson & Rustin (2007) ; Hinnen & Eskens (2007) ; Lippert (2007) . For a recent clinical study of Vadimezan, see: Pili et al. (2010) ; McKeage et al. (2008 McKeage et al. ( , 2009 . For studies of the molecular mechanisms and signal pathways of Vadimezan, see: Zhan et al. (2010) ; Cheng et al. (2010) ; Roberts et al. (2008) . For the biological and pharmacological activity of Vadimezan analogues with structure-activity relationships, see: Gobbi et al. (2006) ; Woon et al. (2005) . For the synthesis and spectroscopic data for Vadimezan, see : Yang & Denny (2009); Atwell et al. (2002) . For related xanthone structures, see: Yu et al. (2008); Zhang et al. (2007) .
Experimental
Crystal data Table 1 Hydrogen-bond geometry (Å , ). Data collection: CrystalClear (Rigaku/MSC, 2008 ); cell refinement: CrystalClear; data reduction: CrystalClear; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 ); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008) ; molecular graphics: SHELXL97 (Sheldrick, 2008) ; software used to prepare material for publication: publCIF (Westrip, 2010) and PLATON (Spek, 2009 Vadimezan: 2-(5,6-dimethyl-9-oxo-9H-xanthen-4-yl)acetic acid S.-J. Zhang and W.-X. Hu
Comment
Tumor vascular disrupting agents (VDA) cause the established vascular structure inside a solid tumor to collapse, depriving the tumor of blood, oxygen and nutrients it needs to survive (McKeage et al., 2010; Head et al., 2010; Ching, 2008; Patterson et al., 2007; Hinnen et al., 2007; Lippert, 2007) . A number of new drug-based VDAs have been developed that are believed to be highly efficient, low toxic, and several of them are currently undergoing clinical trials, among which Vadimezan is the most advanced in Phase III clinical development (Pili et al., 2010; McKeage et al., 2009; McKeage et al., 2008) . The study of antitumor mechanisms and signal pathways of Vadimezan is carried out (Zhan et al., 2010; Cheng et al., 2010; Roberts et al., 2008) , as well as the structure modification of xanthones (Gobbi et al., 2006; Woon et al., 2005) .
The molecular structure of Vadimezan is very important and necessary in understanding of the compound and may help to further elucidate its antivascular effect for the treatment of human cancer. Its crystal structure is reported for the first time in this paper. The structure (Figure 1 ) is similar to other xanthones reported with an essential planar three-ring skeleton and the C atom of the carboxyl group deviates at 1.221 (3) Å from the tricycle plane. In the crystal structure, intermolecular O-H···O (Table 2) hydrogen bonds link the molecules into centrosymmetric dimers, and π-π interactions (Table 1) link these dimers into layers parallel to ac plane. Weak intermolecular C-H···O interactions (Table 2 ) consolidate further the crystal packing (Fig. 2) .
Experimental
Vadimezan was prepared from 3,4-dimethylanthranilic acid according to literature method (Atwell et al., 2002) . Diazotization of 3,4-dimethylanthranilic acid with NaNO 2 and then treatment with KI led to 3,4-dimethyl-2-iodobenzoic acid, which was coupled with 2-hydroxyphenylacetic acid catalyzed by TDA-1 and Cu (I) 
Refinement
H atom attached to carboxyl O atom was located in a difference map and refined with bond restraint O-H = 1.00 (2) Å.
C-bound H atoms were positioned geometrically (C-H 0.95 -0.99 Å). All H atoms were refined as riding, with U iso (H) = 1.2 -1.5 U eq of the parent atoms. Hydrogen atoms attached to C14 are disordered with a refined site occupancy factor 0.50 for each H14A, H14B, H14C, H14D, H14E and H14F.
supplementary materials sup-2 Figures   Fig. 1 . The molecular structure of (I) shown with 30% probability displacement ellipsoids. One component of rotationally disordered methyl group (C14) is shown. 
